薛宏偉教授克拉屈濱 關(guān)于套細(xì)胞淋巴瘤

1、腫瘤淋巴瘤綜合治療科腫瘤淋巴瘤綜合治療科 薛宏偉薛宏偉套細(xì)胞淋巴瘤的臨床診療體會(huì)套細(xì)胞淋巴瘤的臨床診療體會(huì)推測推測 The R-B combination demonstrated a superior PFS and response rate but no difference in OS A survival benefit for the use of R-CHOP over rituximab and FC (R-FC) in older patients with MCL. This study also demonstrated the clear benefit of ritu

2、ximab as maintenance after R-CHOP, 常規(guī)治療常規(guī)治療強(qiáng)化治療強(qiáng)化治療鞏固治療鞏固治療特藥治療特藥治療關(guān)注關(guān)注British Columbia Cancer AgencyTwenty-six patients had low bulk (10 cm) stage IA (12 patients) or IIA (14 patients) MCLAnn Oncol. 2003 Oct;14(10):1555-61累及野放療累及野放療J Clin Oncol. 2009 Mar 10;27(8):1209-13.觀察和等待觀察和等待 pathogenesisNHOO

3、NNNClNH2OH適用癥適用癥臨床受歡迎的藥物特點(diǎn)臨床受歡迎的藥物特點(diǎn)美國中北部腫瘤治療協(xié)作組臨床研究美國中北部腫瘤治療協(xié)作組臨床研究MCLMCL David J. Inwards, Thomas E. Witzig, 美國中北部腫瘤治療協(xié)作組臨床研究美國中北部腫瘤治療協(xié)作組臨床研究21/4381/78結(jié)結(jié) 果果 結(jié)結(jié) 論論2 2例中樞侵犯患者的療效報(bào)道例中樞侵犯患者的療效報(bào)道 Tatsuro Jo, et al. Case Rep Oncol 2012;5:260266 Tatsuro Jo, et al. Case Rep Oncol 2012;5:260266 2 2例中樞侵犯患者的療

4、效報(bào)道例中樞侵犯患者的療效報(bào)道用法用法青醫(yī)附院青醫(yī)附院MCLMCL療效觀察療效觀察年年齡齡姓名姓名病病理理一階段化一階段化療方案療方案二階段化二階段化療方案療方案療效療效1療效療效2肝炎肝炎56張永燦MCL3R-CHOP5RCSDPR乙肝乙肝55王本勛MCL3R-CDOP6RCPRCRu乙肝乙肝67楊金義MCL6RC CR CR乙肝乙肝70李秀蘭MCL3R-CHOP6RCPRCRu乙肝乙肝77蘭奎先MCL5RCCR CR丙肝丙肝52王克明MCL4RCPR 未知未知乙肝乙肝55劉清仁MCL6RFC6RCCR-PDCR未知未知71.5%主要副反應(yīng)主要副反應(yīng)Marlene Troch, et al. Haematologica, 2013,98(2):264-268 Grade/N. Of patientsHematolgicLeukopeina2Lymphopeina7Thrombocytopenia1Anemia-1Pancytopenia0Allergic reactions0Renal insufficiency0Herpes zoster0Fatigue4Pneumonia0Marlene T